|

TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

RECRUITINGSponsored by State University of New York at Buffalo
Actively Recruiting
SponsorState University of New York at Buffalo
Started2025-06-02
Est. completion2026-06
Eligibility
Age18 Months – 11 Years
Healthy vol.Accepted
Locations13 sites

Summary

This is a longitudinal, observational epidemiological study designed to estimate the prevalence of depression, anxiety, and behavior problems in children ages 18 months through 11 years with cystic fibrosis (CF).

Eligibility

Age: 18 Months – 11 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Child with a diagnosis of Cystic fibrosis (CF) actively followed by the CF care team at a participating site
2. Child is age 18 months thru 11 years
3. English and/or Spanish speaking
4. Parent/legal guardian willing and able to give informed consent, and for minor participants ages 7 thru 11 years able to give assent.

Exclusion Criteria:

* Unable or unwilling to participate in study procedures, or at Site PI discretion.

Conditions3

AnxietyCystic Fibrosis (CF)Depression

Locations13 sites

Children's Hospital of Orange County
Orange, California, 92868
Adrianne Alpern, PhD657-767-2730aalpern@choc.org
Children's Hospital Colorado
Aurora, Colorado, 80045
Emily Muther, PhD720- 777-3257Emily.Muther@childrenscolorado.org
Joe DiMaggio
Hollywood, Florida, 33021
Alexandra L Quittner, PhD305-992-2411aquittner@mhs.net
Nemours Foundation
Orlando, Florida, 32827
David Fedele, PhD352-294-5765David.Fedele@nemours.org
Indiana University
Bloomington, Indiana, 47405
Emma M Tillman, PhD, PharmD(317) 274-2797emtillma@iu.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.